Literature DB >> 24957043

Expression profile of CYP1A1 and CYP1B1 enzymes in endometrial tumors.

Ioannis Spyrou1, Stavros Sifakis, Achilles Ploumidis, Alexandros E Papalampros, Evangellos Felekouras, Aristidis M Tsatsakis, Demetrios A Spandidos, Vasilis P Androutsopoulos.   

Abstract

The cytochrome P450 CYP1A1 and CYP1B1 enzymes are phase I extrahepatic enzymes involved in the activation of pro-carcinogenic compounds to carcinogenic metabolites. Although differential overexpression of CYP1A1 and CYP1B1 has been documented at the messenger RNA (mRNA) and protein level, studies that have examined CYP1 expression by enzyme activity assays are limited. In the current study, the expression of CYP1A1 and CYP1B1 was investigated in a panel of human tumors of endometrial origin by quantitative reverse transcriptase PCR (qRT-PCR), Western blotting, and enzyme activity assays. The data revealed that approximately 36 % (5/14) and 43 % (6/14) of the endometrial tumors overexpressed CYP1A1 and CYP1B1 mRNA, whereas in 57 % of the endometrial tumors, CYP1 mRNA levels were downregulated. The mean mRNA levels of CYP1B1 and CYP1A1 in endometrial tumors did not show a significant difference compared to normal tissues (p > 0.05). Western blotting confirmed the qRT-PCR results and CYP1A1 and CYP1B1 proteins were shown to be downregulated in 7/14 (50 %) of the tumors and overexpressed in 4/14 (29 %) of the tumors. As regards to enzyme activity, 21 % (3/14) of the endometrial samples revealed elevated CYP1 activity levels across the tumor counterparts. Overall, the data suggest a putative downregulation of CYP1A1 and CYP1B1 expression in endometrial tumors, whereas overexpression of active CYP1 enzymes in 21 % of the tumors highlights the potential use of the latter enzymes as chemotherapeutic targets in endometrial cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24957043     DOI: 10.1007/s13277-014-2240-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  24 in total

1.  Coordinate regulation of cytochrome P450 1a1 expression in mouse liver by the aryl hydrocarbon receptor and the beta-catenin pathway.

Authors:  Albert Braeuning; Christoph Köhle; Albrecht Buchmann; Michael Schwarz
Journal:  Toxicol Sci       Date:  2011-04-16       Impact factor: 4.849

2.  The flavonoids diosmetin and luteolin exert synergistic cytostatic effects in human hepatoma HepG2 cells via CYP1A-catalyzed metabolism, activation of JNK and ERK and P53/P21 up-regulation.

Authors:  Vasilis P Androutsopoulos; Demetrios A Spandidos
Journal:  J Nutr Biochem       Date:  2012-06-27       Impact factor: 6.048

3.  Disturbed expression of phase I and phase II estrogen-metabolizing enzymes in endometrial cancer: lower levels of CYP1B1 and increased expression of S-COMT.

Authors:  Neli Hevir; Jasna Sinkovec; Tea Lanišnik Rižner
Journal:  Mol Cell Endocrinol       Date:  2010-09-29       Impact factor: 4.102

4.  Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder.

Authors:  Mark Sutherland; Jason H Gill; Paul M Loadman; Jonathan P Laye; Helen M Sheldrake; Nicola A Illingworth; Mohammed N Alandas; Patricia A Cooper; Mark Searcey; Klaus Pors; Steve D Shnyder; Laurence H Patterson
Journal:  Mol Cancer Ther       Date:  2012-10-01       Impact factor: 6.261

5.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.

Authors:  J Ferlay; E Steliarova-Foucher; J Lortet-Tieulent; S Rosso; J W W Coebergh; H Comber; D Forman; F Bray
Journal:  Eur J Cancer       Date:  2013-02-26       Impact factor: 9.162

6.  Functional significance of cytochrome P450 1B1 in endometrial carcinogenesis.

Authors:  Sharanjot Saini; Hiroshi Hirata; Shahana Majid; Rajvir Dahiya
Journal:  Cancer Res       Date:  2009-08-18       Impact factor: 12.701

7.  4-Hydroxylation of estrogens as marker of human mammary tumors.

Authors:  J G Liehr; M J Ricci
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

8.  Arachidonic and eicosapentaenoic acid metabolism by human CYP1A1: highly stereoselective formation of 17(R),18(S)-epoxyeicosatetraenoic acid.

Authors:  Dieter Schwarz; Pyotr Kisselev; Spencer S Ericksen; Grazyna D Szklarz; Alexey Chernogolov; Horst Honeck; Wolf-Hagen Schunck; Ivar Roots
Journal:  Biochem Pharmacol       Date:  2004-04-15       Impact factor: 5.858

9.  4-Hydroxylation of estradiol by human uterine myometrium and myoma microsomes: implications for the mechanism of uterine tumorigenesis.

Authors:  J G Liehr; M J Ricci; C R Jefcoate; E V Hannigan; J A Hokanson; B T Zhu
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-26       Impact factor: 11.205

Review 10.  Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development.

Authors:  Robert D Bruno; Vincent C O Njar
Journal:  Bioorg Med Chem       Date:  2007-05-23       Impact factor: 3.641

View more
  3 in total

Review 1.  Methods for the analysis of transcriptome dynamics.

Authors:  Daniela F Rodrigues; Vera M Costa; Ricardo Silvestre; Maria L Bastos; Félix Carvalho
Journal:  Toxicol Res (Camb)       Date:  2019-07-26       Impact factor: 3.524

2.  Yeast two-hybrid screening identified WDR77 as a novel interacting partner of TSC22D2.

Authors:  Qiao Li; Pan Chen; Zhaoyang Zeng; Fang Liang; Yali Song; Fang Xiong; Xiayu Li; Zhaojian Gong; Ming Zhou; Bo Xiang; Cong Peng; Xiaoling Li; Xiang Chen; Guiyuan Li; Wei Xiong
Journal:  Tumour Biol       Date:  2016-06-23

3.  Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy via screening of a natural product repository.

Authors:  Prashant Joshi; Vinay R Sonawane; Ibidapo S Williams; Glen J P McCann; Linda Gatchie; Rajni Sharma; Naresh Satti; Bhabatosh Chaudhuri; Sandip B Bharate
Journal:  Medchemcomm       Date:  2018-01-08       Impact factor: 3.597

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.